Go Pro
→ Bank of America: 'Digital Dollar Inevitable' (From Decentralized Masters) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$39.33
+0.2%		$38.76
$21.77
▼
$45.14
$3.09B0.84942,727 shs118,533 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$100.96
+0.1%		$103.53
$49.67
▼
$111.86
$6.59B-0.031.10 million shs307,228 shs
VivoPower PLC Ordinary Shares stock logo
VIVO
VivoPower PLC Ordinary Shares
$3.86
+1.3%		$4.34
$1.20
▼
$6.86
$48.37M-0.661.10 million shs156,839 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-0.98%-4.80%+3.10%+31.92%+77.72%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
-0.08%+0.01%+1.24%+0.63%+83.75%
VivoPower PLC Ordinary Shares stock logo
VIVO
VivoPower PLC Ordinary Shares
-6.39%-8.63%+6.72%-33.62%+380,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$39.33
+0.2%		$38.76
$21.77
▼
$45.14
$3.09B0.84942,727 shs118,533 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$100.96
+0.1%		$103.53
$49.67
▼
$111.86
$6.59B-0.031.10 million shs307,228 shs
VivoPower PLC Ordinary Shares stock logo
VIVO
VivoPower PLC Ordinary Shares
$3.86
+1.3%		$4.34
$1.20
▼
$6.86
$48.37M-0.661.10 million shs156,839 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-0.98%-4.80%+3.10%+31.92%+77.72%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
-0.08%+0.01%+1.24%+0.63%+83.75%
VivoPower PLC Ordinary Shares stock logo
VIVO
VivoPower PLC Ordinary Shares
-6.39%-8.63%+6.72%-33.62%+380,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2.85
Moderate Buy$56.0842.72% Upside
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
2.29
Hold$108.117.11% Upside
VivoPower PLC Ordinary Shares stock logo
VIVO
VivoPower PLC Ordinary Shares
2.00
Hold$10.00160.42% Upside

Current Analyst Ratings Breakdown

Latest LNTH, CLDX, and VIVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
8/17/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
8/13/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C+) ➝ Hold (C)
8/7/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$40.00 ➝ $46.00
8/7/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$48.00 ➝ $53.00
8/4/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
CJS Securities logo
CJS Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeMarket Outperform ➝ Market Perform
8/3/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold$125.00 ➝ $102.50
8/3/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold$110.00 ➝ $102.50
8/3/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$102.50
8/3/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$102.50
8/3/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
(Data available from 9/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$158K19,530.61N/AN/A$9.10 per share4.32
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.54B4.27$6.38 per share15.81$20.10 per share5.02
VivoPower PLC Ordinary Shares stock logo
VIVO
VivoPower PLC Ordinary Shares
$60K801.92N/AN/A$1.60 per share2.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$258.76M-$4.35N/AN/AN/AN/A-52.35%-47.61%11/9/2026 (Estimated)
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$233.56M$4.1424.3818.66N/A17.69%28.10%14.35%11/5/2026 (Estimated)
VivoPower PLC Ordinary Shares stock logo
VIVO
VivoPower PLC Ordinary Shares
-$12.79MN/AN/AN/AN/AN/AN/AN/AN/A

Latest LNTH, CLDX, and VIVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$1.06-$0.94+$0.12-$0.94$0.74 million$0.02 million
8/6/2026Q2 2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.30$1.55+$0.25$1.11$363.23 million$388.18 million
6/26/2026Q2 2026
VivoPower PLC Ordinary Shares stock logo
VIVO
VivoPower PLC Ordinary Shares
N/A-$0.23N/A-$0.23N/A$0.01 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
VivoPower PLC Ordinary Shares stock logo
VIVO
VivoPower PLC Ordinary Shares
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
11.82
11.82
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.43
3.06
2.89
VivoPower PLC Ordinary Shares stock logo
VIVO
VivoPower PLC Ordinary Shares
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%
VivoPower PLC Ordinary Shares stock logo
VIVO
VivoPower PLC Ordinary Shares
15.80%

Insider Ownership

CompanyInsider Ownership
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
5.20%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1.70%
VivoPower PLC Ordinary Shares stock logo
VIVO
VivoPower PLC Ordinary Shares
9.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
15078.53 million74.45 millionOptionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1,19365.27 million64.16 millionOptionable
VivoPower PLC Ordinary Shares stock logo
VIVO
VivoPower PLC Ordinary Shares
4112.53 million11.39 millionN/A

Recent News About These Companies

Zenvia (NASDAQ:ZENV) versus VivoPower PLC Ordinary Shares (NASDAQ:VIVO) Financial Analysis
August 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30986272
VivoPower's debt retirement and Nordic restructuring reinforce Outperform case from Noble
August 19, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1097294?snapi
VivoPower to spin off non-Nordic AI data center assets into new Singapore-based platform
August 17, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1097140
VivoPower to spin off non-Nordic AI data center assets into new Singapore-based platform
August 17, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1097140?snapi
VivoPower Approves Independent Listing of 2.2GW Non-Nordic AI Infrastructure Platform, Transferring Capital Expenditure Requirements Whilst Retaining De Facto Control
August 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/17/3346071/0/en/vivopower-approves-independent-listing-of-2-2gw-non-nordic-ai-infrastructure-platform-transferring-capital-expenditure-requirements-whilst-retaining-de-facto-control.html
VivoPower PLC Ordinary Shares (NASDAQ:VIVO) Trading Up 2.8% – Should You Buy?
August 12, 2026  |  defenseworld.netD
VivoPower clears $28.8m founder loan ahead of Nordic data centre push
August 3, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1096454?snapi
VivoPower Fully Retires US$28.8 Million Shareholder Debt Principal, Strengthening Balance Sheet Ahead of Nordic AI Infrastructure Buildout
August 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/03/3337531/0/en/vivopower-fully-retires-us-28-8-million-shareholder-debt-principal-strengthening-balance-sheet-ahead-of-nordic-ai-infrastructure-buildout.html
VivoPower secures $50M investment led by Blue Sky Capital to fund AI data center project
July 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/technology/ai/articles/vivopower-secures-50m-pipe-led-122900759.html
VivoPower secures $50M PIPE led by Blue Sky Capital to fund AI data center project
July 29, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1096208?snapi
VivoPower Secures US$50 Million PIPE At US$7.50 Conversion Price Per Share
July 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/29/3335190/0/en/vivopower-secures-us-50-million-pipe-at-us-7-50-conversion-price-per-share.html
VivoPower announces appointment of Group Finance Director
July 20, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1095707?snapi
VivoPower Appoints Group Finance Director
July 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/20/3329778/0/en/vivopower-appoints-group-finance-director.html
VivoPower positions for scarcity of renewable-backed AI compute sites
July 15, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1095505?snapi
Noble Capital Markets Initiates Equity Research Coverage on VivoPower
July 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/13/3326388/0/en/noble-capital-markets-initiates-equity-research-coverage-on-vivopower.html
VivoPower earns Outperform rating as Noble bets on "power-first" AI strategy
July 13, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1095351?snapi
VivoPower eyes potential earnings boost from battery storage at Norway data center
July 6, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1095003?snapi
VivoPower Targets Up To USD$4 million Incremental Annualized EBITDA from Battery Energy Storage Integration at Norway Data Center
July 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/06/3322702/0/en/vivopower-targets-up-to-usd-4-million-incremental-annualized-ebitda-from-battery-energy-storage-integration-at-norway-data-center.html
VivoPower sharpens AI data center focus, updates separation plans for two units
July 3, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1094919?snapi
VivoPower Reinforces Focus on AI Data Center Business and Provides Update on Non-Core Businesses
July 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/02/3321602/0/en/vivopower-reinforces-focus-on-ai-data-center-business-and-provides-update-on-non-core-businesses.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Celldex Therapeutics stock logo

Celldex Therapeutics NASDAQ:CLDX

$39.33 +0.09 (+0.23%)
As of 01:54 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$100.96 +0.08 (+0.07%)
As of 01:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

VivoPower PLC Ordinary Shares stock logo

VivoPower PLC Ordinary Shares NASDAQ:VIVO

$3.86 +0.05 (+1.31%)
As of 01:30 PM Eastern

VivoPower PLC is engaged in building, owning, and leasing powered land and data center infrastructure for AI compute applications. The group delivers specialized infrastructure solutions across the AI Data Centers, Power-to-X, and Electric Mobility. It is develop and operated infrastructure that enables sovereign nations and institutional partners to secure control over power, data, and national intelligence, supporting AI, compute-intensive workloads, and energy transition use cases.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas